strategic-management

EXHIBIT 5 Large Competitors to J&J
Company Stock Symbol
Amgen Inc. AMGN
Genentech, Inc. Private
Biogen Idec Inc. BHB
Genzyme Corp. GENZ
Merck Serono S.A. Private
Sandoz International GmbH Private
Watson Pharmaceuticals Inc. WPI
Barr Pharmaceuticals Inc. Private
King Pharmaceuticals Inc. KG
Ranbaxy Laboratories Limited Private
Mylan, Inc. MYL
Pfizer Inc. PFE
Chiron Corporation Private
Gilead Sciences Inc. GILD
Medimmune, Inc. Private
Life Technologies Corporation LIFE
Teva Pharmaceutical Industries Limited TEVA
GlaxoSmithKline plc GSK
Sanofi-Aventis SNY
AstraZeneca plc AZN
Abbott Laboratories ABT
Merck & Co. Inc. MRK
Bristol-Myers Squibb Co. BMY
Novartis AG MVS
Eli Lilly LLY
Procter & Gamble PG
Puerto Rico, and Canada. Abbott reported 2008 total revenues of $29,525.5 million with a
net income of $4,880.7 million. 6
Merck & Co. Inc.
A top competitor of J&J is Merck & Co. Inc., which offers treatments and medications for
adults and children over a wide range of applications. Merck has a strong position in the
world of pharmaceuticals with such advancements as Gardasil, the world’s first anticancer
vaccine; diabetes medications; eye disease treatments; and multiple cardiovascular drugs
such as Cozaar and Hyzaar. Merck has a keen understanding of the industry as shown by
its continuous growth and improvement. Recently, Merck and Insmed Inc. reached an
agreement in which Merck will acquire Insmed for $130 million to access their follow-on
biologics platform and all assets associated with follow-on biologics. In 2008, Merck
reported total revenues of $23,850.3 million with a net income of $7,808.4 million. 7
Novartis
Exhibit 6 provides a comparison of J&J with Novartis.
Novartis offers over 60 pharmaceutical products including one of the most well-known
drugs, Ritalin, and has received more approvals than any other pharmaceutical company in the
industry since 2000. In addition to its wide range of pharmaceuticals, Novartis also sells
generic drugs through their division Sandoz, making Novartis the only company to have
obtained a leadership position in both pharmaceutical and generic drugs. The company supports
an employee-centered philosophy in that every employee will be heard and is given the
CASE 21 • JOHNSON & JOHNSON — 2009 207